Skip to content Skip to footer

Destiny Pharma Evaluates Strategic Options to Fast-track XF-73 Nasal Program

Destiny Pharma, a leading UK-based biotechnology company, has embarked on a strategic review of its XF-73 nasal program. The move follows the firm’s announcement of its audited financial results for the year ending 31 December 2023.

Destiny Pharma, known for its innovative approach in developing medicines that prevent life-threatening infections, hopes that this strategic evaluation will advance the XF-73 nasal to Phase 3 clinical trials. The process will focus on reassessing potential partnerships and licensing deals concerning the nasal product, consequently hoping to halve the originally planned Phase 3 trial costs.

XF-73 nasal has garnered significant attention from potential partners for its commercial appeal. Positive feedback has propelled Destiny Pharma to adopt a new clinical trial design that could potentially lead to considerable savings in the subsequent trial phase.

Moreover, a recent study on XF‐73, as published in Frontiers in Cellular and Infection Microbiology, demonstrated its potency against antibiotic-resistant and sensitive bacterial strains. This seals XF‐73 position as a promising tool in surgical infection control, particularly in cardiac surgery patients, as evidenced by infection prevention success in a landmark Phase 2b clinical study.

In NTCD-M3 development, Destiny Pharma has secured a promising collaboration deal with Sebela Pharmaceuticals, worth up to $570m in potential payments. Further enhancing its competitive profile, the company aims to deliver a clinical and commercial product supply transition from liquid to solid dosage.

While the company has strengthened its board and management during this period, Destiny Pharma has also significantly reduced its loss before tax to £6.4 million from £7.7 million in 2022. Despite challenges, the company is financially robust, with research and development expenditure at £3.3 million, other operating expenses at £3.8 million and year-end cash and cash equivalents standing at £6.4 million, it is well funded through Q1 of 2025.

As part of broadening market understanding and gauging the potential of XF-73 nasal, an ongoing analysis is underway. This exercise will paint a clear picture of the product’s value as a preventive treatment and how best it can be commercialized and capitalized upon by the industry.

Through this comprehensive examination of its strategic position, Destiny Pharma aims to expedite the advancement of its XF-73 nasal product, consequently ensuring the best chance of success.


Sign Up to Our Newsletter

Be the first to know the latest updates

[yikes-mailchimp form="1"]